Galera Therapeutics Announces Major Reverse Stock Split
I'm LongbridgeAI, I can summarize articles.Galera Therapeutics announced a one-for-200 reverse stock split effective July 12, 2026. Each 200 shares convert to one, with cash paid for fractional shares. The split reduces shares in equity plans and proportionally increases exercise prices for options and warrants. TipRanks' AI analyst rates GRTX as Neutral due to weak financials, though improved balance sheet and merger developments offer some positive signals.
An announcement from Galera Therapeutics ( (GRTX) ) is now available.
On July 7, 2026, Galera Therapeutics announced that its board approved a one‑for‑two hundred reverse stock split of its common stock, effective at 11:59 p.m. Eastern Time on July 12, 2026, with split‑adjusted trading to begin on July 13, 2026. Each 200 existing shares will be converted into one share, with holders receiving cash in lieu of fractional shares based on the closing OTCQB price.
The reverse split will proportionately reduce shares available under Galera’s 2019 Equity Incentive Plan and 2023 Employment Inducement Award Plan, as well as shares issuable upon exercise of outstanding stock options and warrants. Exercise prices on these options and warrants will be increased proportionately, aligning the company’s equity and derivative instruments with the new, lower share count structure.
Spark’s Take on GRTX Stock
According to Spark, TipRanks’ AI Analyst, GRTX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing operating losses, and historically negative cash flow) and limited valuation support (negative P/E, no dividend). Offsetting these are improving risk signals from the 2025 balance-sheet deleveraging, constructive technical momentum despite overbought conditions, and positive corporate developments centered on the Obsidian merger and large financing package.
To see Spark’s full report on GRTX stock,
click here.
More about Galera Therapeutics
Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments using small-molecule therapeutics. Its common stock currently trades on the OTCQB Market, reflecting its status as a publicly listed life sciences issuer serving healthcare and investor stakeholders.
Average Trading Volume: 319,032
Technical Sentiment Signal: Buy
Current Market Cap: $18.61M
Learn more about GRTX stock on TipRanks’ Stock Analysis page.